Lebanese guidelines for osteoporosis assessment and treatment: Who to test? What measures to use? When to treat?

Journal of Clinical Densitometry

Volumn 8, Issue 2, 2005, Pages 148-163

  Fuleihan, Ghada El Hajj ^a   Baddoura, Rafic ^b   Awada, Hassane ^b   Okais, Jad ^b   Rizk, Paul ^c   McClung, Michael ^d  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c RIZK HOSPITAL   (Lebanon)

^d OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Bone density; Guidelines; Lebanese; Measures; Test; Treat

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCITRIOL; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; TIBOLONE;

BONE DENSITY; DEMOGRAPHY; HEALTH CARE COST; HISTORY OF MEDICINE; HORMONE SUBSTITUTION; HUMAN; LEBANON; MEDICAL ASSESSMENT; MEDICAL PRACTICE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; VALIDATION PROCESS; VERTEBRA FRACTURE; WORLD HEALTH ORGANIZATION;

EID: 26244463529     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:8:2:148     Document Type: Article

References (140)

1. El-Hajj Fuleihan GR, Baddoura R, Awada H, Rizk P, McClung M. 2002 Guidelines for osteoporosis assessment and treatment. Leb Med J 50(3):75-125.
2. Report of a WHO Study Group. 1994. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Tech Rep Seri 843:1-129.
3. Wasnich R. 1993. Bone mass measurement: prediction of risk. Am J Med 95 (Suppl A):6S-10S.
4. Delmas PD. 2000 Do we need to change the WHO definition of osteoporosis? Osteoporos Int 11:189-191
5. Laupacis A, Sekar N, Stiell IG. 1997 Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 277:488-494.
6. Law MR, Wald NJ, Meade TW. 1991 Strategies for prevention of osteoporosis and hip fracture. Br Med J 303:453-459.
7. Johnston CC Jr, Slemenda CW. 1993 Risk assessment: theoretical considerations. Am J Med 95 (Suppl A):2S-5S.
8. Cummings SR, Black D. 1995 Bone mass measurement and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 98(Suppl A):24S-28S.
9. Ross PD, Davis JW, Epstein RS, Wasnich RD. 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919-923.
10. Cummings SR. 1996 Treatable and untreatable risk factors for hip fracture. Bone 18:165S-167S.
11. Kanis JA, McCloskey EV. 1996 Evaluation of the risk of hip fracture. Bone 18:127S-132S.
12. Silman AJ. 1995 The patient with fracture: the risk of subsequent fracture. Am J Med 98(Suppl A):12S-16S.
13. Carroll J, Testa MA, Erat K, LeBoff MS, El-Hajj Fuleihan G. 1997 Modeling fracture risk using bone density, age and years since menopause Am J Prev Med 13:447-452.
14. Blake GM, Gluer CC, Fogelman I. 1997 Bone densitometry current status and future prospects. Br J Radiol 70:S177-S186.
15. Levis S, Altman R. 1998 Bone densitometry. Clinical considerations. Arthritis Rheum 41:577-587.
16. Rizzoli, Solsman D, Bonjour JP. 1995 The role of DEXA of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis. Am J Med 98(2A):33S-36S
17. Sturtridge W, Lentle B, Hanley DA. 1996 Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. The use of bone densitometry measurement in the diagnosis and management of osteoporosis. CMAJ 155: 924-929.
18. Bracker MD, Watts NS. 1998 How to get most out of bone densitometry? Results can help assess fracture risk and guide therapy. Postgrad Med 104:77-79, 83-86.
19. Melton LJ III, Kan SH, Wahner HW, Riggs BL. 1988 Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 41:985-994.
20. Christiansen C. 1998 Practical application of risk assessment. Osteoporos Int Suppl 1:S43-S46.
21. Christiansen C. 1995 What should be done at the time of menopause? Am J Med 98(Suppl A):56-58.
22. Black DM. 1995 Why elderly women should be screened and treated to prevent osteoporosis? Am J Med 98(Suppl A):66S-75S.
23. Cummings SR, Nevitt MC, Browner WS, et al. 1995 Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773.
24. Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC Jr. 1990 Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med 112:96-101.
25. Johnston CC. 1996 Development of clinical practice guidelines for prevention and treatment of osteoporosis. Calcif Tissue Int 59(Suppl 1):S30-S33.
26. Baran DT, Faulkner KG, Genant HK, Miller PD, Pacifici R. 1997 Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry. Calcif Tissue Int 61:433-440.
27. El-Hajj Fuleihan G. 1999 Osteoporosis: an overview of practice guidelines for bone density measurements and osteoporosis treatment strategies. Leb Med J 47:221-228.
28. Eddy DM, Delmas P, Burckhardt P, et al. 1998 Osteoporosis: review of the evidence for prevention, diagnosis, treatment and cost-effectiveness analysis. Osteoporos Int Suppl 4:7S-80S.
29. Lewiecki M, Kendler, Kiebzak G, et al. 2004 Special report on the official positions of the International Society for Clinical Densitometry. Osteoporos Int 15:779-784.
30. Anon. 1996 Clinical practice guidelines for diagnosis and management of osteoporosis. Scientific advisory board, Osteoporosis Society of Canada. CMAJ 155:1113-1133.
31. Hodgson SF, Watts NB, Bilezikian JP, et al. 2001 AACE 2001 medical guidelines for clinical practice for the prevention and treatment of osteoporosis. Endocr Prac 7:293-312.
32. Anon. 2001 Recommendations for the prevention and treatment of gluco-corticoid induced osteoporosis: 2001 update. ACR Ad Hoc Committee on GIO. Arthritis Rheum 44(7):1496-1503.
33. Anon. 2002 Position statement. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 9:84-101.
34. Nelson HD, Helfand M, Woof SH, Allan JD. 2002 Screening for postmenopausal osteoporosis: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 137:529-541.
35. Kanis JA, Black D, Cooper C, et al. 2002 On behalf of the International Osteoporosis Foundation, USA. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 13:527-536.
36. Kanis JA, Delmas P, Burckhardt P, Cooper C, Togerson D. 1997 Guidelines for diagnosis and management of osteoporosis on behalf of the European Foundation of Osteoporosis. Osteoporos Int 7:390-406.
37. Kanis JA, Gluer CC. 2000 An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of scientific advisors of the International Osteoporosis Foundation. Osteoporos Int 11:192-202.
38. Sambrook P, O'Neill S, Diamond T, Flicker L, MacLennan A. 2000 Postmenopausal osteoporosis treatment guidelines. Aust Fam Physician 29(8):756-758.
39. Cadarette SM. 2001 Evaluation of decision rules for referring for bone densitometry by DEXA. JAMA 286:57-63.
40. Weinstein L, Ullery B. 2000 Identification of at-risk women for osteoporosis screening. Am J Obstet Gynecol 183:547-549.
41. Michaelsson K, Bergestrom R, Mallim H, Holmberg L, Wolk A. 1996 Screening for osteopenia and osteoporosis: selection by body composition. Osteoporos Int 6:120-126.
42. Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C. 1998 Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 4:37-48.
43. Cadarette SM, Jaglal SB, Kreiger N, McIsaac WJ, Darlington GA, Tu JV. 2000 Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ 162:1289-1294.
44. Siris E, Miller P, Barrett-Connor E, Abbott T, Sherwood L, Berger M. 1998 Design of NORA, the National Osteoporosis Risk Assessment Program. A longitudinal US registry of postmenopausal women. Osteoporos Int Suppl 1:S62-S69.
45. De Laet CE, Van Hout BA, Burger H, et al. 1997 Bone density and risk of hip-fracture in men and women: cross-sectional analysis. Br Med J 315:221-225.
46. Selby PL, Davies M, Adams JE. 2000 Do men and women fracture bones at similar bone densities? Osteoporos Int 11(2):153-157.
47. Melton LJ III, Atkinson EJ, O'Connor MK, et al. 1998 Bone density and fracture risk in men. J Bone Miner Res. 13:1915-1923.
48. Orwoll E. 2000 Perspective. Assessing bone density in men. J Bone Miner Res 15:1867-1870.
49. Orwoll ES, Belknap JK, Klein RF. 2001 Gender specificity in the genetic determinants of peak bone mass. J Bone Miner Res 16:1962-1971.
50. Anon. 1993 Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94: 646-650.
51. Anon. 2001 Osteoporosis prevention diagnosis and therapy: NIH Consensus Development on Osteoporosis Prevention Diagnosis and Therapy. JAMA 285:785-795.
52. Kanis JA, Devogelaer J-P, Gennari C. 1996 Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 6:256-261.
53. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. 1992 Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005-1010.
54. Melton LJ III. 2000 Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 15:2309-2314.
55. Bouxsein ML, Augat P. 1999 Biomechanics of bone. In: Quantitative US. Njeh CF, ed. London: Martin Dunitz, 21-46.
56. Wasnich RD, Ross PD, Heilbrun LK, Vogel JM. 1985 Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 153:745-751.
57. Hui SL, Slemenda CW, Johnston CC Jr. 1988 Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81: 1804-1809.
58. Hui SL, Slemenda CW, Johnston CC Jr. 1989 Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 111:355-361.
59. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W. 1992 Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 7:633-638.
60. Melton LJ III, Atkinson LJ, O'Fallon WM, Wahner HW, Riggs BL. 1993 Long term fracture prediction by bone mineral assessed at different skeletal sites J Bone Miner Res. 8:1227-1233.
61. Hans D, Dargent-Molina, Schott AM, et al. 1996 Ultrasonographic heel measurements to predict hip fractures in elderly women: the EPIDOS Prospective Study. Lancet 348:511-514.
62. Bauer DC, Gluer CC, Cauley JA, et al. 1997 Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 157:629-634.
63. Schott AM, Cormier C, Hans D, et al. 1998 How hip and whole body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporosis Int 8:247-254.
64. Faulkner K, Abbott TA III, Furman WD, et al. 2000 Fracture risk assessment in NORA is comparable across peripheral sites. J Bone Miner Res 15S: Abstract 1021.
65. Blake GM, Fogelman I. 2001 Peripheral or central densitometry: does it matter which technique we use? J Clin Densitom 4:83-96.
66. Hochberg MC, Ross PD, Black D, et al. 1999 Larger increases in bone mineral density during alendronate therapy are associated with lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246-1254.
67. Wasnich RD, Miller PD. 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
68. Faulkner K. 2000 Bone matters: are density increases necessary to reduce fractures risk? J Bone Miner Res 15:183-187.
69. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. 2002 Changes in bone density and turnover explain the reduction in incidence of nonvertabral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 87:1586-1592
70. Cummings SR, Karpf DB, Harris F, et al. 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. JAMA 112:281-289.
71. Marcus R, Wong M, Heath H III, Stock J. 2002 Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fractures as an end point. Endocrinol Rev 23:16-37.
72. Miller PD, Bonnick SL, Johnston CC, et al. 1998 The challenges of peripheral bone density testing. Which patients need additional central density skeletal measurements. J Clin Densitom 1:211-217.
73. Gluer CC. 1997 Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group. J Bone Miner Res 12:1280-1288.
74. De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. 1998 Hip fracture prediction in elderly men and women: validation of the Rotterdam study. J Bone Miner Res 13:1587-1593.
75. Siris ES, Miller PD, Barrett-Connor E, et al. 2001 Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822.
76. Formica CA, Nieves JW, Cosman F, Garrett P, Linsday R. 1998 Comparative assessment of bone mineral measurements using dual X-ray absorptiometry and peripheral quantitative tomography. Osteoporos Int 8:460-467.
77. Jergas M, Breitenseher M, Gluer CC, Yu W, Genant HK. 1995 Estimates of volumetric bone density from projectional measurements improve the discriminative capability of dual X-ray absorptiometry. J Bone Miner Res 10:1101-1110.
78. Genant HK, Engelke K, Fuerst T, et al. 1996 Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 11:707-730.
79. Bonnick SL, Johnston CC, Kleerekoper M, et al. 2001 Importance of precision in bone density measurements. J Clin Densitom 4:105-110.
80. LeBoff MS, El-Hajj Fuleihan G, Angell JE, Chung S, Curtis K. 1992 Dual-energy X-ray absorptiometry of the forearm: reproducibility and correlation with single photon absorptiometry. J Bone Miner Res 7:841-846.
81. El Hajj Fuleihan GE, Testa M, Angell J, Porrino N, LeBoff MS. 1995 Reproducibility of DXA densitometry: a model for bone loss estimates. J Bone Miner Res 10:1004-1014.
82. Arabi A, Salamoun M, Ballocet H, El-Hajj Fuleihan G. 2005 Densitometer type and impact on risk assessment for osteoporosis. J Clin Densitom in Press.
83. Cummings SR, Black DM, Nevitt MC, et al. 1993 Bone density at various sites for prediction of hip fracture. The Study of Osteoporotic Fractures Research Group. Lancet 341:72-75.
84. Marshall D, Johnell O, Wedel H. 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254-1259.
85. Genant H, Grampp S, Gluer C, et al. 1994 Universal standardization for dual X-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 10:1503-1514.
86. Faulkner KG, Von Stetten E, Miller P. 1999 Discordance in patient classification using T-scores. J Clin Densitom 2:343-350.
87. Lofman O, Larsson L, Toss G. 2000 Bone mineral density in diagnosis of osteoporosis. Reference population, definition of peak bone mass, and measured site determine prevalence. J Clin Densitom 3:177-186.
88. Miller P, Njeh C, Jankowski L, Lenchik L. 2002 What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? J Clin Densitom 5:S39-S45.
89. El-Desouki M. 1995 Bone mineral density of the spine and femur in the normal Saudi population. Saudi Med J 16:30-35.
90. Ghannam NN, Hammani MM, Bakheet SM, Khan BA. 1999 Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation. Calcif Tissue Int 65:23-28.
91. Maalouf G, Salem S, Sandid M, et al. 2000 Bone mineral density of the Lebanese reference population. Osteoporos Int 11:756-764.
92. Dougherty G, Al-Marzouk N. 2001 Bone density measured by dual-energy X-ray absorptiometry in healthy Kuwaiti women. Calcif Tissue Int 68:225-229.
93. El-Hajj Fuleihan G, Baddoura R, Awada H, Salam N, Salamoun M, Rizk P. 2002 Low peak bone mineral density in healthy young Lebanese subjects. Bone 31:520-528.
94. El Hajj-Fuleihan G, Deeb M. 1999 Hypovitaminosis D in a sunny country. N Engl J Med 340:1840-1841.
95. El-Hajj Fuleihan G, Nabulsi M, Choucair M, et al. 2001 Hypovitaminosis D in healthy school children. Pediatrics 4:1-7.
96. Al-Nuaim AR, Kremli M, Al-Nuaim M, Sandgki S. 1995 Incidence of proximal femur fracture in an urbanized community in Saudi Arabia. Calcif Tissue Int 56:536-538.
97. Memom A, Popsula WM, Tantawy AY, Abdul-Ghafar S, Suresh A, Al-Rowaih A. 1998 Incidence of hip fracture in Kuwait. Int J Epidemiol 27:860-865.
98. Arabi A, Baddoura R, Awada H, Salamoun M, El-Hajj Fuleihan G. 2004 Hypovitaminosis D in a sunny country and its relation to musculoskeletal health in the elderly. J Bone Mina Res 19(Suppl 1):Abstract 1047.
99. Baddoura R, Okais J, Awada H. 2001 Incidence fracturaire après 50 ans et implications d'osteoporose dans la population Libanaise. Rev Epidemiol Sante Publique 49:27-32.
100. El-Hajj Fuleihan G, Badra M, Tayim A, et al. 2001 Lebanese patients with hip fractures are relatively young, but have osteoporosis. J Bone Miner Res (Suppl 1):Abstract M 337.
101. Baddoura R, Salam N, Okais J, Dagher F, Awada H. 2002 Does the risk of hip fracture using hip BMD measurements vary across Caucasian populations? Ann Rheum Dis 61(Suppl 1): Abstract FR10304.
102. Greenspan SL, Maitland-Ramsey L, Myers E. 1996 Classification of osteoporosis in the elderly is dependant on site-specific analysis. Calcif Tissue Int 58:409-414.
103. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas P. 1997 Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 12:683-690.
104. Deng HW, Li J-L, Li J, Davies KM, Recker RR. 1998 Heterogeneity of bone mineral density across skeletal sites and its clinical implications. J Clin Densitom 1:339-353.
105. Cann CE, Rutt BK, Genant HK. 1983 Effect of extraosseous calcification on vertebral mineral measurement. Calcif Tissue Int 35:667.
106. Rand T, Seidl G, Kianberger F, et al. 1997 Impact of spinal degenerative changes on the evaluation of bone mineral density with dual-energy X-ray absortiometry (DXA). Calcif Tissue Int 60:430-433.
107. Silverberg SJ, Shane E, De La Cruz L, et al. 1989 Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-290.
108. Leib E, Lewiecki EM, Binkley N, Hamdy R. 2004 Official positions of the International Society for Clinical Densitometry. J Clin Densitom 7:1-5.
109. Faulkner KG, Roberts LA, McClung MR. 1996 Discrepancies in normative data between Lunar and Hologic DXA. Osteoporosis Int 7:432-438.
110. Meunier PJ, Delmas PD, Eastell R et al. 1999 Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. Clin Ther 21:1025-1044.
111. Genant HK, Cooper C, Poor G, et al. 1999 Interim report and recommendations of the World Health Organization Task-force for osteoporosis. Osteoporos Int 10:259-264.
112. Hochberg M. 2000. Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging 17:317-330.
113. Tannenbaum C, Clark J, Schwarzamn K, et al. 2002 Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431-4437.
114. Royal College of Physicians. 2001 Osteoporosis. 2001 Clinical Guidelines for Prevention and Treatment. Update on Pharmacological Interventions and an Algorithm for Management. London: Royal College of Physicians. Available at http://www.rcplondon.ac.uk/pubs/wp_osteo_update.htm.
115. Brown JP, Josse RG, the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(Suppl 10):1S-S34.
116. Black DM, Cummings SR, Karpf DB, et al. 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
117. Black DM, Thompson DE, Bauer DC, et al. 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118-4124.
118. Harris ST, Watts NB, Genant HK, et al. 1999 Effect of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344-1352.
119. Reginster JY, Minne HW, Sorensen OH, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
120. Ettinger B, Black DM, Mitlak BH, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3 year randomized clinical trial. JAMA 192:637-645.
121. McClung MR, Geusens P, Miller PD, et al. 2001 Effect of risedronate on the risk of hip fracture in elderly Women. N Engl J Med 344:333-340.
122. Adachi JD, Bensen WG, Brown J, et al. 1997 Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 337:382-387.
123. Saag KG, Emkey R, Schnitzer TJ, et al. 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299.
124. Cohen S, Levy RM, Keller M, et al. 1999 Risedronate therapy prevents corticosteroid-induced bon loss. A twelve-month, multicenter, randomized, placebo-controlled parallel group study. Arthritis Rheum 42:2309-2318.
125. Orwoll E, Ettinger M, Weiss S, et al. 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610.
126. Ringe JD, Faber H, Dorst A. 2001 Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252-5255.
127. Cummings SR, Black DM, Thomson DE et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082.
128. Kanis J, Johnell O, Black D, et al. 2003 Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293-300.
129. Storm T, Thamsborg G, Steiniche T, Genant H, Sorensen. 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
130. Watts NB, Harris ST, Genant H, et al. 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
131. Lufkin EG, Wahner HW, O'Fallon WM, et al. 1992 Treatment of postmenopausal osteoporosis with transdemial estrogen. Ann Intern Med 117:1-9.
132. Chesnut CH III, Silverman S, Andriano K, et al. 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporosis fractures study. PROOF Study Group. Am J Med 109:267-276.
133. Rossouw JE, Anderson GL, Prentice RL, et al. Writing group for the women's Health Initiative. 2002 Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333.
134. Chapuy MC, Arlot ME, DuBouef F, et al. 1992 Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637-1642.
135. Dawson-Hughes B, Harris SS, Krall EA, et al. 1997 Effect of calcium and vitamin D supplementation trial in men and women age 65 years or older. N Engl J Med 337:670-676.
136. Reid DM, Hughes RA, Laan R FJM, et al. 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006-1013.
137. Watts NB, Josse RG, Hamdy RC, et al. 2003 Residronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542-549.
138. Juby AG, De Geus-Wenceslau Cm. 2002 Evaluation of osteoporosis treatment in seniors after hip fractures. Osteoporos Int 13:205-210.
139. Watts NB, Harris ST, Genant HK. 2001 Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty. Osteoporos Int 12:429-437.
140. Watts NB. 2003 Is percutaneous vertebral augmentation (vertebroplasty) effective treatment for painful vertebral fractures? Am J Med 114:326-328.